-
Treatment and prognosis of newly diagnosed advanced-stage extranodal natural killer / T cell lymphoma: a single-center real-world study across two decades. Chemotherapy (IF 3.3) Pub Date : 2023-11-20 Yu-Ce Wei,Fei Qi,Bo Chen,Chang-Gong Zhang,Hui Fang,Di Zhang,Shu-Nan Qi,Yue Chai,Ye-Xiong Li,Mei Dong
INTRODUCTION Although there is now a consensus on asparaginase-based chemotherapy regimens in treatment of advanced-stage extranodal natural killer / T cell lymphomas (ENKTCLs), patient survival in the real-world setting is still not optimistic according to previous literature reports, and the optimal chemotherapeutic regimens and integration of different therapeutic methods under the concept of combined-modality
-
Daptomycin-induced eosinophilic pneumonia: a case report and systematic review. Chemotherapy (IF 3.3) Pub Date : 2023-11-14 Andrea Di Lorenzo,Lorenzo Vittorio Rindi,Laura Campogiani,Alessandra Imeneo,Grazia Alessio,Pier Giorgio Pace,Alessandra Lodi,Benedetta Rossi,Angela Maria Antonia Crea,Pietro Vitale,Dimitra Kontogiannis,Vincenzo Malagnino,Massimo Andreoni,Marco Iannetta,Loredana Sarmati
Introduction Acute eosinophilic pneumonia (AEP) is a rare respiratory condition caused by eosinophil accumulation in the pulmonary tissue that can be related to drug administration. Daptomycin, an antibiotic active against gram-positive bacteria, is one of the leading causes of AEP among drugs. In order to raise awareness of this rare syndrome, in our work we have described a case of an 82 years-old
-
Review Article title: Natural Compounds with Antimicrobial Activities in oral Candida infections during head and neck radiotherapy. Chemotherapy (IF 3.3) Pub Date : 2023-11-14 Elena Imperia,Graziana Bonincontro,Annamaria Altomare,Giovanna Simonetti,Giovanni Gherardi,Elisa Brasili,Camilla Badiali,Manuela Bove,Gabriella Pasqua,Laura De Gara,Michele Cicala,Michele Pier Luca Guarino
BACKGROUNDS Oral colonization and infections are frequently observed in patients during and soon after radiation therapy (RT). Infective mucositis is a common side effect associated with cancer therapy, characterized by an inflammation of the oral mucous membranes with histological mucosal and submucosal changes. Ulcerative mucositis is responsible for significant pain, impairing the patient's nutritional
-
FDG-PET in Relapsed/Refractory Hodgkin Lymphoma: a practical approach. Chemotherapy (IF 3.3) Pub Date : 2023-09-14 Valeria Tomarchio,Luigi Rigacci
BACKGROUND Positron emission tomography (PET) with the use of 18F-fluorodeoxyglucose (FDG), implemented with low dosage Computer Tomography (CT), is to be considered as the most important evolution of imaging in the management and assessment of classical Hodgkin Lymphoma (cHL) patients. SUMMARY According to Lugano response criteria, FDG-PET is mandatory to define metabolic response to frontline therapy
-
Fighting antimicrobial resistance and healthcare-associated infections in EU-JAMRAI: the One-Health response from Italy. Chemotherapy (IF 3.3) Pub Date : 2023-09-06 Luca Busani,Roberta Creti,Elisa Fabbro,Francesca Prestinaci,Annalisa Pantosti,Anna Maria Marella,Silvio Brusaferro,Michela Sabbatucci
Antimicrobial resistance (AMR) is a serious health threat, and it has high priority among the European public health agenda. The development and implementation of the National Action Plans (NAP) with a One Health perspective to fight AMR was supported in 2017 by the European Union (EU) through a Joint Action on Antimicrobial Resistance and Healthcare Associated Infections (EU-JAMRAI). The Italian National
-
A Multicentric Castleman disease associated with mixed warm and cold antibody-mediated AHA responsive to siltuximab. Chemotherapy (IF 3.3) Pub Date : 2023-08-25 Federica Plano,Salvatrice Mancuso,Giulia Maria Camarda,Maria Giulia Butera,Giuseppe Sucato,Giuseppe Alecci,Ada Maria Florena,Salvatore Perrone,Sergio Mario Siragusa
Castleman disease (CD) is nonclonallymphoproliferative disorders defined by hypertrophy of lymph nodes. The multicentric form (MCD), in which multiple lymph node stations are involved, is not associated with HHV8 infection, but considered idiopathic, although IL-6 appears to play a central role in its pathogenesis. Here we report the case of a patient that presented with mixed AIHA and adenopathy,
-
Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients. Chemotherapy (IF 3.3) Pub Date : 2023-08-17 Zhi Rao,Si-Ming Guo,Yan-Ming Wei
INTRODUCTION Monitoring of AUC24 was updated recommendation in the guideline for the therapeutic drug monitoring (TDM) of vancomycin in Chinese pharmacological society published in 2020. Vancomycin pharmacokinetic profiles are diverse and unique in critically ill patients because of the drastic variability of the patients' physiological parameters, while the study for population pharmacokinetic (PPK)
-
Complete remission of a diffuse large B-cell lymphoma in a young patient, with severe tuberous sclerosis, treated with metronomic chemotherapy and ibrutinib: a case report. Chemotherapy (IF 3.3) Pub Date : 2023-08-07 Marta Banchi,Tiziana Lanzolla,Arianna Di Napoli,Arianna Bandini,Guido Bocci,Maria Christina Cox
TTuberous sclerosis (TS) is a rare autosomal dominant genetic multisystem disease caused by mutations in either the TSC1 or TSC2 gene and results in the growth of non-cancerous masses in several organs. Diffuse large B-cell lymphoma (DLBCL) is the predominant non-Hodgkin lymphoma in adolescents and young adults. Metronomic chemotherapy (mCHEMO) ca be defined as the frequent, regular administration
-
Ceramide analogue 5cc overcomes TRAIL-resistance by enhancing JNK activation and repressing XIAP expression in metastatic colon cancer cells. Chemotherapy (IF 3.3) Pub Date : 2023-07-10 Qiqian Huang,Feiyan Liu
Introduction:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered to be an effective apoptosis inducer due to its selectivity for tumor cells. However, many cancer cells, especially metastatic cancer cells, often exhibit resistance to TRAIL because their apoptotic pathway is impaired or their pro-survival pathway is overactivated. TRAIL-resistance is the main obstacle to current
-
Why metformin should not be used as an oxidative phosphorylation inhibitor in cancer patients. Chemotherapy (IF 3.3) Pub Date : 2023-06-21 Minas Sakellakis
BACKGROUND Preclinical studies have suggested that metformin exerts antitumor effects on various types of cancers. However, the results of human clinical trials have been inconsistent. SUMMARY Metformin is widely considered to be a prime example of a clinically relevant compound that inhibits oxidative phosphorylation (OXPHOS). However, the efficacy of metformin in inhibiting OXPHOS in cancer patients
-
Efficacy and safety of low-dose apatinib combined with chemotherapy as second-line treatment for advanced gastric cancer: a meta-analysis. Chemotherapy (IF 3.3) Pub Date : 2023-06-20 Liang Wang,Juyuan Li,Huamin Chen
INTRODUCTION At present, there are several studies on low-dose apatinib combined with chemotherapy as a second-line treatment of advanced gastric cancer (AGC), but the conclusions are controversial. Therefore, this meta-analysis aims to evaluate the efficacy and safety of low-dose apatinib combined with chemotherapy as a second-line treatment of AGC. METHODS Nine databases were searched for records
-
Long-term progression-free survival of a pre-treated patient with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil. Chemotherapy (IF 3.3) Pub Date : 2023-06-19 Gerlinde Maria Michl,Florian M Vogt,Andreas Nouriani,Roland Ladurner,Marcus Kremer,Timo Reisländer,Marlies Michl
Trifluridine/tipiracil is approved for the use in later or last line setting in previously treated mCRC patients who progressed on standard anti-tumor drugs including 5-fluorouracil (5-FU), Irinotecan, Oxaliplatin, anti-VEGF- and anti-EGFR-antibodies or who are not considered candidates for those standard therapies. In this report, we describe a 67-year old male patient with KRAS-mutated mCRC and metachronous
-
Efficacy of PD-1 inhibitors in first-line treatment for advanced gastroesophageal junction and gastric cancer by subgroups: A systematic review and meta-analysis. Chemotherapy (IF 3.3) Pub Date : 2023-06-16 Shengqi Fei,Yu Lu,Jing Chen,Jia Qi,Wenxuan Wu,Beidi Wang,Yaxuan Han,Kefan Wang,Xiaying Han,Haiyan Zhou,Jun Wang,Jian Chen
Background PD-1 inhibitors have been approved for the first-line treatment of patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. However, the results of several clinical trials are not entirely consistent, and the dominant population of first-line immunotherapy for advanced gastric/gastroesophageal junction cancer still needs to be precisely determined
-
Endobronchial presentation of Hodgkin's lymphoma responding to pembrolizumab: a case report. Chemotherapy (IF 3.3) Pub Date : 2023-06-13 Marianna Gentilini,Beatrice Casadei,Alice Morigi,Ginevra Lolli,Marco Ferrari,Matteo Carella,Lisa Argnani,Pier Luigi Zinzani
An endobronchial localization of Hodgkin lymphoma is rare, and few experiences since the 1900s have been reported in literature. Here we report the first case of a relapsed/refractory Hodgkin lymphoma with a critical vegetative mass at the level of the trachea successfully treated with pembrolizumab.
-
Treatment with brivudine in immunocompromised pediatric patients with herpes zoster. Chemotherapy (IF 3.3) Pub Date : 2023-05-18 Clara Vogel,Laura Wetzel,Peter Wutzler,Bernd Gruhn
INTRODUCTION Herpes zoster (HZ) is caused by endogenous reactivation of latent varicella-zoster virus (VZV) that persists in sensory ganglia after primary infection. The incidence and severity of HZ increase during immunosuppression. Especially immunocompromised patients are at high risk of developing a cutaneous rash and suffering from delayed healing of lesions. Bromovinyl deoxyuridine (brivudine)
-
Meningococcal conjunctivitis in a 54-year-old man: case report and review of the literature. Chemotherapy (IF 3.3) Pub Date : 2023-05-07 Giovanni Gherardi,Pier Luigi Surico,Marco Coassin,Antonio Di Zazzo,Silvia D'Arezzo,Silvia Angeletti,Carla Fontana,Nicola Petrosillo
Neisseria meningitidis represents an uncommon pathogen of acute bacterial conjunctivitis. In this brief report we describe a case of meningococcal conjunctivitis in an immunocompetent adult male, with a review of the literature. The patient went to the outpatient ophtalmology clinic complaining ofsevere ocular discomfort, burning and redness for more than 2 weeks and, at slit lamp examination, he was
-
Acute hepatitis E infection during chemotherapy for lung cancer: a case report Chemotherapy (IF 3.3) Pub Date : 2023-04-25 Hiroki Okumura, Atsushi Miyamoto, Fumitaka Suzuki, Hisashi Takaya
Acute hepatitis E, one of the causes of acute liver injury, has been increasingly diagnosed in developed countries in recent years. Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. Thus, viral hepatitis, including hepatitis E, must be ruled out in the diagnosis of DILI. A 78-year-old woman with lung adenocarcinoma
-
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES Chemotherapy (IF 3.3) Pub Date : 2023-03-31 Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna
ABSTRACT Background Acute myeloid leukemia (AML) is a life-threatening disease whose treatment is made difficult by a number of mutations or receptor overexpression in the proliferating cellular clones. Life expectancy of patients diagnosed with new, relapsed-refractory or secondary AML has been improved by drugs targeted at such moieties. Regrettably, however, clinical use of new AML drugs is complicated
-
A 7-day decitabine included conditioning regimen accelerated donor hematopoietic engraftment while reduced the occurrence of mucositis without interfering with prognosis Chemotherapy (IF 3.3) Pub Date : 2023-03-29 Yuan Yuan Shi, Long Su, Zeng Yan Liu, Yi Geng Cao, Xin Chen, Rong Li Zhang, Qing Zhen Liu, Jian Feng Yao, Wei Hua Zhai, Qiao Ling Ma, Er Lie Jiang, Ming Zhe Han
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard and curative treatment strategy for patients with hematologic malignancies. Recently, decitabine included regimens are investigated by several studies including ours, which may prevent relapse of primary malignant diseases. Methods: This study was to retrospectively evaluate a 7-day decitabine included regimen
-
Circulating endothelial cell (CEC) kinetic in patients with Multiple Myeloma (MM) who receive Au-HSCT (Autologous Hematopoietic Stem Cell Transplantation) Chemotherapy (IF 3.3) Pub Date : 2023-03-09
Introduction: Neoangiogenesis has a crucial role in Multiple Myeloma (MM) and Circulating Endothelial Cells (CECs) contribute to neovascularization by inducing tumor progression and metastasis and by repairing damage to bone marrow vasculature after stem cell transplantation (HSC). We recently proved in a national multicenter study, the possibility to reach a high level standardization in CEC count
-
Circulating endothelial cell (CEC) kinetic in patients with Multiple Myeloma (MM) who receive Au-HSCT (Autologous Hematopoietic Stem Cell Transplantation) Chemotherapy (IF 3.3) Pub Date : 2023-03-09
Introduction: Neoangiogenesis has a crucial role in Multiple Myeloma (MM) and Circulating Endothelial Cells (CECs) contribute to neovascularization by inducing tumor progression and metastasis and by repairing damage to bone marrow vasculature after stem cell transplantation (HSC). We recently proved in a national multicenter study, the possibility to reach a high level standardization in CEC count
-
Arrhythmia in Bruton Tyrosine Kinase Inhibitor treated patients: Unanswered Questions Chemotherapy (IF 3.3) Pub Date : 2023-03-07
(No abstract allowed for commentary)
-
-
Arrhythmia in Bruton Tyrosine Kinase Inhibitor treated patients: Unanswered Questions Chemotherapy (IF 3.3) Pub Date : 2023-03-07
(No abstract allowed for commentary)
-
-
LncRNA BCAR4 promotes oxaliplatin resistance in colorectal cancer by modulating miR-484-3p/RAB5C expression Chemotherapy (IF 3.3) Pub Date : 2023-01-19 Xianting Li, Xiaojiao Chen, Chendong Fu, Ming Xie, Shurui Ouyang
Background Oxaliplatin based chemotherapy resistance is a major cause of recurrence in patients with colorectal cancer (CRC). Increasing evidence indicates that LncRNA BCAR4 is involved in the occurrence and development of various cancers. However, the effect of BCAR4 on CRC chemotherapy resistance remains unclear. Methods Real-time quantitative PCR and western blotting were used to detect the expression
-
Long Non-Coding RNA BCAR4 Promotes Oxaliplatin Resistance in Colorectal Cancer by Modulating miR-484-3p/RAB5C Expression Chemotherapy (IF 3.3) Pub Date : 2023-01-19
Background: Oxaliplatin-based chemotherapy resistance is a major cause of recurrence in patients with colorectal cancer (CRC). Increasing evidence indicates that lncRNA BCAR4 is involved in the occurrence and development of various cancers. However, the effect of BCAR4 on CRC chemotherapy resistance remains unclear. Methods: Real-time quantitative PCR and Western blotting were used to detect the expression
-
Evaluation of a novel combination therapy, based on trifluridine/tipiracil and fruquintinib, against colorectal cancer Chemotherapy (IF 3.3) Pub Date : 2023-01-09 Mamoru Nukatsuka, Akio Fujioka, Hideki Nagase, Gotaro Tanaka, Hiroaki Hayashi
Introduction: Trifluridine/tipiracil hydrochloride (FTD/TPI, Lonsurf®) is an oral antineoplastic agent that has been approved as a late-stage chemotherapy for colorectal cancer. Its major mechanism of action is the dysfunction of tumoral DNA including DNA strand breaks and decreased replication. Fruquintinib (ELUNATE®) is a novel kinase inhibitor that selectively inhibits the vascular endothelial growth
-
Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer Chemotherapy (IF 3.3) Pub Date : 2023-01-09
Introduction: Trifluridine/tipiracil hydrochloride (FTD/TPI, Lonsurf®) is an oral antineoplastic agent that has been approved as late-stage chemotherapy for colorectal cancer. Its major mechanism of action is the dysfunction of tumoral DNA including DNA strand breaks and decreased replication. Fruquintinib (ELUNATE®) is a novel kinase inhibitor that selectively inhibits the vascular endothelial growth
-
Initial therapeutic approach with pembrolizumab in synchronous multiple cancers, including non-small cell lung cancer highly positive for programmed death-ligand 1 expression Chemotherapy (IF 3.3) Pub Date : 2022-12-28 Tomonobu Koizumi, Shintaro Kanda, Takashi Kobayashi, Yoh-ichiro Iwasa, Akemi Matsuo
Treatment of synchronous multiple primary cancers is clinically difficult. We report four cases of synchronous primary cancers, including advanced and metastatic non-small cell lung cancer (NSCLCs) highly positive for programmed death-ligand 1 (PD-L1) expression and initially treated with pembrolizumab. Pembrolizumab was efficacious in two patients with NSCLC lesions, followed by chemoradiotherapy
-
Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression Chemotherapy (IF 3.3) Pub Date : 2022-12-28
Treatment of synchronous multiple primary cancers is clinically difficult. We report four cases of synchronous primary cancers, including advanced and metastatic non-small cell lung cancer (NSCLCs) highly positive for programmed death ligand-1 (PD-L1) expression and initially treated with pembrolizumab. Pembrolizumab was efficacious in 2 patients with NSCLC lesions, followed by chemoradiotherapy for
-
IMPACT OF PRE TRANSPLANT SALVAGE THERAPIES ON OUTCOME OF HODGKIN LYMPHOMA PATIENTS PERFORMING ALLOGENEIC TRANSPLANT Chemotherapy (IF 3.3) Pub Date : 2022-12-22 Fulvia Fanelli, Stefan Hohaus, Maria Cantonetti, Giuseppe Cimino, Elsa Pennese, Roberta Battistini, Eugenio Galli, Raffaella Cerretti, Anna Proia, Federica Fatone, Ida Provenzano, Elisabetta Abruzzese, Erica Finolezzi, Alessandro Pulsoni, Luigi Rigacci
Background: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors) showed interesting results and were used as bridge therapies to allotransplant. Aim: The aim of this retrospective study in Lazio Region was to evaluate the impact of these
-
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant Chemotherapy (IF 3.3) Pub Date : 2022-12-22
Background: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory (R/R) to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors [CPI]) showed interesting results and were used as bridge therapies to allotransplant. Aim: The aim of this retrospective study in Lazio region was to evaluate the
-
Drug interactions causing warfarin overdose in a patient with a pancreatic cancer : a case report. Chemotherapy (IF 3.3) Pub Date : 2022-11-29 Marie Moussouni, Véronique GRAFF, Franck COUTURIER, Hugo HERRSCHER
Mistletoe, Viscum album, is a medicinal plant used in complementary medicine in oncology. Patients don’t necessarily mention to their oncologist this phytotherapeutic treatment which may be responsible for unsuspected drug interactions. Some patients are adept at taking medicinal plants, a practice often unknown to health professionals who take care of it. This case reports drugs interactions leading
-
Drug interactions causing warfarin overdose in a patient with a pancreatic cancer : a case report. Chemotherapy (IF 3.3) Pub Date : 2022-11-29
Mistletoe, Viscum album, is a medicinal plant used in complementary medicine in oncology. Patients don’t necessarily mention to their oncologist this phytotherapeutic treatment which may be responsible for unsuspected drug interactions. Some patients are adept at taking medicinal plants, a practice often unknown to health professionals who take care of it. This case reports drugs interactions leading
-
-
-
-
-
Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death Chemotherapy (IF 3.3) Pub Date : 2022-11-10 Giuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, Giorgio Minotti, Marco Vitolo
Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically improved by the introduction of ibrutinib, a Bruton’s kinase (BTK) inhibitor. In this review we aimed to summarize and critically evaluate the association between first and second generation BTK inhibitors and the risk of atrial fibrillation (AF) and ventricular arrhythmias (VA). Summary: Since the first clinical
-
Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death Chemotherapy (IF 3.3) Pub Date : 2022-11-10
Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically improved by the introduction of ibrutinib, a Bruton’s kinase (BTK) inhibitor. In this review we aimed to summarize and critically evaluate the association between first and second generation BTK inhibitors and the risk of atrial fibrillation (AF) and ventricular arrhythmias (VA). Summary: Since the first clinical
-
Targeted therapy of non-small cell lung cancer and liver cancer: functional nanocarriers for the delivery of cisplatin and tissue factor pathway inhibitor-2 Chemotherapy (IF 3.3) Pub Date : 2022-11-03 MingZhong Ma, JianWei He, Bo Gao, JianXun Cao, DaMing Li, YongChun Li, Gang Huang, Xing Zhou
Introduction: To construct folic acid-modified PEGylated paramagnetic nanoparticles (MNP) co-carrying tissue factor pathway inhibitor-2 (TFPI-2) and cisplatin (CDDP), and to study the molecular-targeting and inhibitory effects of the nanocomposite on non-small cell lung cancer (NSCLC) and liver cancer. Methods: Nanocomposites were prepared using amino-modified iron oxide nanoparticles as carriers,
-
Fulminant type 1 diabetes mellitus caused by long-term nivolumab administration followed by nivolumab plus cabozantinib combination Chemotherapy (IF 3.3) Pub Date : 2022-11-03 Takamasa Homma, Norio Yoshida, Kuniaki Tanaka, Masaya Isemura, Shota Torii, Teruhisa Kinoshita, Hideki Esaki, Takashi Sakakibara, Norio Takimoto
Nivolumab, an immune checkpoint inhibitor (ICI), is now used to treat many advanced cancers, including non-small cell lung cancer (NSCLC) and renal cancer. Immune-related adverse events are characteristic side effects of ICIs. Among them, fulminant type 1 diabetes mellitus is an infrequent but potentially life-threatening and clinically significant concern. Cabozantinib is known as a multi-kinase inhibitor
-
Clinical analysis of extrapulmonary neuroendocrine carcinoma: a retrospective and single institution experience Chemotherapy (IF 3.3) Pub Date : 2022-11-03 Taiki Okumura, Takuro Noguchi, Nodoka Sekiguchi, Takashi Kobayashi, Shintaro Kanda, Koichi Ida, Tomonori Minagawa, Shigeo Tokumaru, Takeji Umemura, Tomonobu Koizumi
Introduction: Extrapulmonary neuroendocrine carcinoma (EPNEC) is a clinicopathological entity distinct from neuroendocrine carcinoma (NEC) of the lung. Here, we reviewed the clinical features, treatment modalities, and prognosis of EPNEC patients in a single-institution series. Methods: We retrospectively reviewed the medical records of EPNEC patients, and examined the clinical profiles and treatment
-
Clinical analysis of extrapulmonary neuroendocrine carcinoma: a retrospective and single institution experience Chemotherapy (IF 3.3) Pub Date : 2022-11-03
Introduction: Extrapulmonary neuroendocrine carcinoma (EPNEC) is a clinicopathological entity distinct from neuroendocrine carcinoma (NEC) of the lung. Here, we reviewed the clinical features, treatment modalities, and prognosis of EPNEC patients in a single-institution series. Methods: We retrospectively reviewed the medical records of EPNEC patients, and examined the clinical profiles and treatment
-
Targeted Therapy of Non-Small Cell Lung Cancer and Liver Cancer: Functional Nanocarriers for the Delivery of Cisplatin and Tissue Factor Pathway Inhibitor-2 Chemotherapy (IF 3.3) Pub Date : 2022-11-03
Introduction: The aim of the study was to construct folic acid-modified PEGylated paramagnetic nanoparticles (MNPs) co-carrying tissue factor pathway inhibitor-2 (TFPI-2) and cisplatin (CDDP), and to study the molecular-targeting and inhibitory effects of the nanocomposite on non-small cell lung cancer (NSCLC) and liver cancer. Methods: Nanocomposites were prepared using amino-modified iron oxide nanoparticles
-
Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination Chemotherapy (IF 3.3) Pub Date : 2022-11-03
Nivolumab, an immune checkpoint inhibitor (ICI), is now used to treat many advanced cancers, including non-small cell lung cancer (NSCLC) and renal cancer. Immune-related adverse events are characteristic side effects of ICIs. Among them, fulminant type 1 diabetes mellitus is an infrequent but potentially life-threatening and clinically significant concern. Cabozantinib is known as a multikinase inhibitor
-
Initiating treatment with low Fluorouracil dose and titrating according to blood levels in patients treated with a 46-hour continuous infusion. Chemotherapy (IF 3.3) Pub Date : 2022-10-21 Ahmad Waleed Khatib, Samuel Maxwell Selub, Anton Uryvaev, Jalal Baranseh, Ayelet Shai
Introduction: Fluorouracil (5-FU) pharmacokinetics are variable, leading to risk of toxicity in some patients and under-dosing in others. Therapeutic drug monitoring (TDM) of 5-FU was shown to reduce toxicity and increase efficacy. This study assessed the clinical utility of starting treatment with 70-80% of BSA calculated dose and titrating according to 5-FU blood levels and toxicity. Methods: A retrospective
-
Initiating treatment with low Fluorouracil dose and titrating according to blood levels in patients treated with a 46-hour continuous infusion. Chemotherapy (IF 3.3) Pub Date : 2022-10-21
Introduction: Fluorouracil (5-FU) pharmacokinetics are variable, leading to risk of toxicity in some patients and under-dosing in others. Therapeutic drug monitoring (TDM) of 5-FU was shown to reduce toxicity and increase efficacy. This study assessed the clinical utility of starting treatment with 70-80% of BSA calculated dose and titrating according to 5-FU blood levels and toxicity. Methods: A retrospective
-
Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting Chemotherapy (IF 3.3) Pub Date : 2022-09-15 Chih-Jung Chen, Hanh T.H. Nguyen, Chih-Hao Huang, Hwei-Chung Wang, Chen-Teng Wu, Yao-Chung Wu, Geng-Yan He, Chiahung Chou, Hsiang-Wen Lin, Liang-Chih Liu
Background: This study aimed to examine the effectiveness and safety of eribulin used as an early-line (i.e., first/second-line; EL) versus late-line (i.e., third-line and beyond; LL) chemotherapy for recurrent advanced or metastatic breast cancer (A/MBC) patients. Methods: This study conducted a retrospective observation of A/MBC patients initiating eribulin between January 1, 2015, and June 30, 2019
-
Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting Chemotherapy (IF 3.3) Pub Date : 2022-09-15
Background: This study aimed to examine the effectiveness and safety of eribulin used as an early-line (EL, i.e., first-/second-line) versus late-line (LL, i.e., third-line and beyond) chemotherapy for recurrent advanced or metastatic breast cancer (A/MBC) patients. Methods: This study conducted a retrospective observation of A/MBC patients initiating eribulin between January 1, 2015, and June 30,
-
SARS-CoV-2 infection in patients treated with azacitidine and venetoclax for acute leukemia – a report of a case series treated in a single institution Chemotherapy (IF 3.3) Pub Date : 2022-09-14 Joanna Drozd-Sokolowska, Krzysztof Mądry, Joanna Barankiewicz, Katarzyna Kobylińska, Przemysław Biecek, Jagoda Rytel, Ewa Karakulska-Prystupiuk, Kamila Skwierawska, Aleksander Salomon-Perzyński, Tomasz Stokłosa, Grzegorz Władysław Basak
Introduction Venetoclax combined with azacitidine (AZA-VEN) constitutes an option for the treatment of acute myeloid leukemia. There is however no data on the COVID-19 incidence and outcome in patients treated with AZA-VEN. Methods Patients with acute leukemia (AL) treated with AZA-VEN at single institution were included in this prospective observational study. Results Thirteen patients were enrolled
-
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution Chemotherapy (IF 3.3) Pub Date : 2022-09-14
Introduction: Venetoclax combined with azacitidine (AZA-VEN) constitutes an option for the treatment of acute myeloid leukemia. There are, however, no data on the COVID-19 incidence and outcome in patients treated with AZA-VEN. Methods: Patients with acute leukemia treated with AZA-VEN at a single institution were included in this prospective observational study. Results: Thirteen patients were enrolled
-
MIC discrepancies between parenteral and oral anti-staphylococcal β-lactams among MSSA Chemotherapy (IF 3.3) Pub Date : 2022-08-24 Brandy N. Hernandez, Thomas Dilworth, Jacob Kesner, Keenan Ryan, Haedi Thelen, Renée-Claude Mercier
Introduction: Recent evidence has shown that oral antibiotic therapy is not inferior to IV antibiotic therapy in the treatment of complicated Staphylococcus aureus infections. Therefore, oral antibiotic therapy is now frequently prescribed in clinical practice due to cost benefit, ease of administration, decrease complications rate and lack of need for an IV access. In vitro susceptibility testing
-
Safety Signal between Azacitidine and Pericarditis Chemotherapy (IF 3.3) Pub Date : 2022-08-18 Brandon Chu, Ajit Venkatakrishnan, Pushkar Aggarwal
Background: Drug-induced pericarditis is an important cause of pericarditis and if un-noticed and un-managed can lead to constrictive pericarditis, pericardial effusion and cardiac tamponade. Objective: The objective of this analysis was to determine if a significant signal exists between Azacitidine use and pericarditis. Methods: A pharmacovigilance analysis was performed using the FDA Adverse Event
-
Curcumin Suppresses the Progression of Colorectal Cancer by Improving Immunogenic Cell Death Caused by Irinotecan Chemotherapy (IF 3.3) Pub Date : 2022-07-27 Cunliang Zhu, Zhaobi Fang, Lei Peng, Fan Gao, Wei Peng, Fengqian Song
Background: Irinotecan (IRI) is a common chemotherapeutic drug for colorectal cancer; however, the mechanism underlying its immunomodulatory effect remains unclear. Curcumin (CUR), an adjuvant drug with anti-inflammatory and antitumor effects, has been studied extensively, although its synergistic antitumor effect remains unclear. Methods: The effects of CUR and IRI on oxidative stress and their antitumor
-
Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy Chemotherapy (IF 3.3) Pub Date : 2022-07-26 Ryan Morse, Rohit G. Ganju, Rishi Neeranjun, Gregory N. Gan, Ying Cao, Prakash Neupane, Kiran Kakarala, Yelizaveta Shnayder, Christopher E. Lominska
Abstract Introduction: Standard of care for radiosensitization in head and neck squamous cell carcinoma (HNSCC) is concurrent chemoradiotherapy (CCRT) with high-dose cisplatin. The optimal chemoradiation regimen for patients medically unfit for cisplatin is unclear. We compared our experience with concurrent cetuximab versus other cytotoxic non-cisplatin agents. Methods: We reviewed 53 patients between
-
Fusidic acid and its major active metabolite penetration into cerebrospinal fluid for assessing treatment of intracranial infections. Chemotherapy (IF 3.3) Pub Date : 2022-07-08 Zhi Rao, Zhong-fang He, Mao-hua Zheng, Zi-long Dang, Gang Yang, Yong-hong Zhang, Ning Lu, Yu-hui Wei
Fusidic acid (FA) had the excellent antimicrobial effects due to its unique mechanism of action. Since 1962, FA has been widely used in the systemic and topical treatment of staphylococcal infections, and exhibit a well characterized potency against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase negative Staphylococci
-
Lung adenocarcinoma harboring triple rare EGFR exon18 mutations rapidly developed resistance to multiple therapies Chemotherapy (IF 3.3) Pub Date : 2022-06-28 Yuyao Liu, Yuanqiang Wu, Fang Wu, Chunhong Hu
Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths worldwide. Its medical significance has spurred broad investigations into its treatment and prognosis. Shortly after the oncogenic driver mutations were identified, targeted therapies for NSCLC developed rapidly, including the discovery of tyrosine kinase inhibitors (TKIs). Epidermal growth factor receptor TKIs (EGFR-TKIs)
-
How I treat localized soft tissue sarcomas: update on diagnosis, risk-stratification and treatment Chemotherapy (IF 3.3) Pub Date : 2022-06-21 Alessandro Mazzocca, Flavia Paternostro, Alessandro Minelli, Marianna Silletta, Carlo Greco, Sergio Valeri, Sara Ramella, Giuseppe Tonini, Bruno Vincenzi
Background: Adult-type soft tissue sarcomas (STS) are rare tumors representing about 1% of all adult malignant tumors. Their extreme histological heterogeneity places them among the most challenging fields of diagnostic pathology. The variability of clinical and prognostic presentation between the various histotypes reflects the different management that should be followed on a case-by-case basis.